BioInvenu

Executive Summary

BioInvenu, a San Diego-based private company founded in 2018, developed the LinkLight cell-based protein-protein interaction (PPI) assay platform, which enabled real-time monitoring of intracellular PPI dynamics. The platform and all associated services, cell lines, and products have been acquired by Reaction Biology Corporation, a contract research organization specializing in biochemical and cell-based assays. As a result, BioInvenu is no longer an independent operating entity; its technology is now integrated into Reaction Biology's service offerings. This acquisition provides Reaction Biology with a differentiated tool for studying protein interactions, potentially accelerating drug discovery projects for clients. However, BioInvenu itself has no standalone pipeline or commercial products, and its future prospects are tied entirely to the success of the acquirer's integration and commercialization efforts.